Clinuvel Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Clinuvel Pharmaceuticals' CEO ist Philippe Wolgen , ernannt in Nov 2005, hat eine Amtszeit von 18.67 Jahren. Die jährliche Gesamtvergütung beträgt A$6.39M , bestehend aus 24.9% Gehalt und 75.1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.84% der Aktien des Unternehmens, im Wert von A$51.96M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.2 Jahre bzw. 6.5 Jahre.

Wichtige Informationen

Philippe Wolgen

Geschäftsführender

AU$3.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	47.2%
Amtszeit als Geschäftsführer	18.9yrs
Eigentum des Geschäftsführers	6.9%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	5yrs

Jüngste Management Updates

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Philippe Wolgen im Vergleich zu den Einnahmen von Clinuvel Pharmaceuticals verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	AU$4m	AU$2m	AU$36m
Mar 31 2024	n/a	n/a	AU$33m
Dec 31 2023	n/a	n/a	AU$30m
Sep 30 2023	n/a	n/a	AU$30m
Jun 30 2023	AU$6m	AU$2m	AU$31m
Mar 31 2023	n/a	n/a	AU$29m
Dec 31 2022	n/a	n/a	AU$26m
Sep 30 2022	n/a	n/a	AU$24m
Jun 30 2022	AU$7m	AU$1m	AU$21m
Mar 31 2022	n/a	n/a	AU$22m
Dec 31 2021	n/a	n/a	AU$24m
Sep 30 2021	n/a	n/a	AU$24m
Jun 30 2021	AU$5m	AU$2m	AU$25m
Mar 31 2021	n/a	n/a	AU$23m
Dec 31 2020	n/a	n/a	AU$21m
Sep 30 2020	n/a	n/a	AU$18m
Jun 30 2020	AU$3m	AU$2m	AU$15m
Mar 31 2020	n/a	n/a	AU$15m
Dec 31 2019	n/a	n/a	AU$15m
Sep 30 2019	n/a	n/a	AU$16m
Jun 30 2019	AU$1m	AU$894k	AU$18m
Mar 31 2019	n/a	n/a	AU$17m
Dec 31 2018	n/a	n/a	AU$16m
Sep 30 2018	n/a	n/a	AU$15m
Jun 30 2018	AU$2m	AU$818k	AU$13m

Vergütung im Vergleich zum Markt: PhilippeDie Gesamtvergütung ($USD4.24M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Australian ($USD849.92K).

Entschädigung vs. Einkommen: PhilippeDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Philippe Wolgen (61 yo)

18.9yrs

Amtszeit

AU$3,742,412

Vergütung

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Philippe Wolgen	CEO, MD & Director	18.9yrs	AU$3.74m	6.86% A$ 48.0m
Dennis Wright	Chief Scientific Officer	12.1yrs	AU$782.61k	0.38% A$ 2.6m
Peter Vaughan	Chief Financial Officer	less than a year	keine Daten	keine Daten
Lachlan Hay	Chief Operations Officer	no data	keine Daten	keine Daten
Malcolm Bull	Head of Australian Operations & Investor Relations	no data	keine Daten	keine Daten
Rose Quadbeck-Diel	Senior Vice President of Regulatory Affairs	less than a year	keine Daten	keine Daten
Azza Hamila	Head of Quality Assurance & Drug Safety	less than a year	keine Daten	keine Daten
Claire Newstead-Sinclair	Company Secretary	less than a year	keine Daten	keine Daten

0.8yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: CUVDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.7 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Philippe Wolgen	CEO, MD & Director	19yrs	AU$3.74m	6.86% A$ 48.0m
Brenda Shanahan	Non-Executive Director	17.7yrs	AU$85.00k	0.23% A$ 1.6m
Pearl Grimes	Non-Executive Director	less than a year	keine Daten	keine Daten
Matthew Pringle	Non-Executive Director	less than a year	keine Daten	keine Daten
Susan Smith	Non-Executive Director	5.1yrs	AU$80.00k	0.00084% A$ 5.9k
Jeffrey Rosenfeld	Non-Executive Chairman	4.9yrs	AU$91.67k	0.0063% A$ 44.1k
Karen Agersborg	Non-Executive Director	6.8yrs	AU$75.00k	0.011% A$ 77.1k
Guy van Dievoet	Non-Executive Director	less than a year	keine Daten	keine Daten

5.0yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: CUVDie Vorstandsmitglieder gelten als erfahren (6.5 Jahre durchschnittliche Amtszeit).

Clinuvel Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

No independent directors

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Recent updates

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 17%

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Price target increased by 18% to AU$30.32

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Price target decreased by 7.4% to AU$25.01

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 13% to AU$31.12

Price target decreased by 7.2% to AU$27.50

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Investor sentiment deteriorates as stock falls 20%

Now 22% undervalued

First half 2023 earnings released: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Price target increased by 11% to AU$28.94

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

No independent directors

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Now 20% undervalued

Investor sentiment improved over the past week

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

Now 22% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to AU$27.32

Investor sentiment deteriorated over the past week

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

Investor sentiment improved over the past week

Price target increased to AU$33.92

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

CEO, MD & Director recently sold AU$2.6m worth of stock